Category: Vyvgart
-
Argenx stock gets H.C. Wainwright nod on Vyvgart growth and pipeline progress By Investing.com
•
On Friday, HC Wainwright reaffirmed a Buy rating on biopharmaceutical company argenx SE (NASDAQ: ARGX), with a firm price target of $448.00. The Company’s confidence in argenx is rooted in the Company’s successful introduction of Vyvgart for the treatment of myasthenia gravis (MG), which has been recognized as one of…